Swiss Re AI Stock Analysis
Want to see SSREY full AI Analyst Report?
Swiss Re (SSREY) AI Stock Analysis
Swiss Re
(Other OTC:SSREY)
The score is driven primarily by solid financial performance (strong profitability and improved leverage) and a constructive earnings update (reiterated guidance, strong H1 results, and robust capital). Technicals are supportive with a clear uptrend, while valuation is notably favorable (low P/E and strong dividend yield). The main constraints are uneven cash-flow quality signals and earnings durability risks highlighted on the call (new business CSM declines and reliance on reserve releases).
Swiss Re (SSREY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $53.82B
- Dividend Yield
- 4.40%
- Average Volume (3M)
- 24.54K
- Price to Earnings (P/E)
- 11.0
- Beta (1Y)
- 0.32
- Revenue Growth
- -3.85%
- EPS Growth
- 30.01%
- Country
- US
- Employees
- 14,893
- Sector
- Financial
- Sector Strength
- 68
- Industry
- Insurance - Reinsurance
Swiss Re Business Overview & Revenue Model
Company Description
Swiss Re AG, along with its various group entities, provides a comprehensive suite of services globally, including extensive wholesale reinsurance, direct insurance offerings, and other innovative methods for risk transfer, complemented by associated...
How the Company Makes Money
Swiss Re primarily makes money by taking on insurance risk from other insurers (and, in some businesses, directly from customers) in exchange for premiums, and by investing the assets it holds to pay future claims. A key revenue stream is reinsurance...
Swiss Re Earnings Call Summary
The call presented a predominantly positive operational and financial picture: strong H1 net income (USD 2.8B), high ROE (23%), robust P&C combined ratio (76.7%), solid Life & Health Re results, healthy investment returns (4.0% ROI) and a very strong capital position (SST ~264%). Management also announced an increased cost-reduction target and continued active capital return (buyback). Offsetting risks include notable declines in new business CSM across segments, pricing pressure in specific lines (non-proportional property, parts of Specialty, Corporate rates), rising P&C expense ratio, and questions about the sustainability of large short-tail reserve releases. Overall, the positives (underwriting results, capital, investments, cost discipline) materially outweigh the headwinds related to new-business profitability and selective pricing pressure, but the latter warrant monitoring going into 2027.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated a full‑year net income target of USD 4.5bn (H1 net income USD 2.8bn, >60% of target) and highlighted strong H1 metrics — group ROE 23% — while setting specific business targets and near‑term expectations: Life & Health H1 net income just over USD 1.0bn with a 2026 net income target of USD 1.7bn, an insurance service result of USD 1.2bn and a CSM release of USD 758m (annualized ~9%); P&C Re H1 insurance service result USD 1.8bn, combined ratio 76.7% (full‑year target <85%), new business CSM USD 1.6bn (vs USD 2.2bn prior) and USD 6–7bn of treaty renewals to end‑June; Corporate Solutions H1 combined ratio 86.1%, insurance service result USD 578m, CSM release ~USD 400m and new business CSM USD 201m (vs USD 262m prior); midyear renewals showed 11% volume growth and year‑to‑date premium volume +0.5% with nominal pricing broadly flat (casualty mid‑single‑digit increases, non‑prop property down high single digits), year‑to‑date loss assumptions +4.4% (explaining a ~4.6% risk‑adjusted price decline), investment ROI 4.0% with recurring income USD 2bn, estimated group SST 264% (up 14pp since Jan, ~5pp temporary benefit), ~60% of a USD 1.5bn buyback executed, an increased operating cost‑saving target of USD 500m by 2028 (run‑rate, reflected in FY2029), and management expects mid‑triple‑digit reserve releases to help offset renewal headwinds.
Swiss Re Financial Statement Overview
Summary
Strong earnings recovery and margin expansion into 2025, with improved leverage and strong recent ROE. Offsetting factors are uneven revenue growth and choppy/less reliable cash-flow signals (declining FCF and inconsistent coverage metrics), which reduce confidence in consistency of cash conversion.
Income Statement
74PositiveBalance Sheet
78PositiveCash Flow
52Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.22B | 48.19B | 46.76B | 43.64B | 46.04B | 45.94B |
| Gross Profit | 31.10B | 48.19B | 43.14B | 40.32B | 38.24B | 37.70B |
| EBITDA | 7.03B | 6.59B | 4.27B | 4.26B | 1.65B | 3.07B |
| Net Income | 5.01B | 4.76B | 3.24B | 3.11B | 472.00M | 1.44B |
Balance Sheet | ||||||
| Total Assets | 132.85B | 134.01B | 127.23B | 179.58B | 170.68B | 181.57B |
| Cash, Cash Equivalents and Short-Term Investments | 3.93B | 2.74B | 88.64B | 88.38B | 85.61B | 4.15B |
| Total Debt | 9.45B | 8.98B | 7.26B | 9.82B | 11.04B | 11.19B |
| Total Liabilities | 108.33B | 108.71B | 103.99B | 163.21B | 157.87B | 157.89B |
| Stockholders Equity | 24.46B | 25.11B | 23.11B | 22.31B | 12.70B | 23.57B |
Cash Flow | ||||||
| Free Cash Flow | 2.37B | 3.04B | 3.13B | 4.09B | 2.93B | 4.10B |
| Operating Cash Flow | 2.37B | 3.04B | 3.13B | 4.09B | 2.93B | 4.10B |
| Investing Cash Flow | 1.94B | -2.29B | -407.00M | -362.00M | -2.34B | -2.14B |
| Financing Cash Flow | -4.00B | -2.14B | -2.97B | -3.22B | -1.24B | -2.10B |
Swiss Re Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SSREY, the sentiment is Positive. The current price of 45.65 is below the 20-day moving average (MA) of 46.27, above the 50-day MA of 44.19, and above the 200-day MA of 41.37, indicating a neutral trend. The MACD of 0.43 indicates Positive momentum. The RSI at 50.81 is Neutral, neither overbought nor oversold. The STOCH value of 7.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SSREY.
Swiss Re Peers Comparison
Overall Rating
ACGL81Outperform
SPNT80Outperform
RGA78Outperform
RNR76Outperform- SSREY74Outperform
EG65Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ACGL | 81Outperform | $35.68B | 8.85 | 18.35% | ― | -5.29% | 14.08% |
| SPNT | 80Outperform | $3.06B | 6.39 | 21.64% | ― | 18.14% | 163.19% |
| RGA | 78Outperform | $17.90B | 10.52 | 13.15% | 1.37% | 22.58% | 99.93% |
| RNR | 76Outperform | $14.29B | 10.06 | 13.52% | 0.46% | -21.18% | -3.27% |
| SSREY | 74Outperform | $49.57B | 11.00 | 20.19% | 4.40% | -3.85% | 30.01% |
| Sector * | 68Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
| EG | 65Neutral | $15.82B | 9.09 | 12.52% | 1.87% | -8.72% | 250.85% |
* Financial Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SSREY | Swiss Re AG | 45.65 | 2.52 | 5.85% | |
| ACGL | Arch Capital | 109.61 | 17.80 | 19.39% | |
| EG | Everest Group, Ltd. | 427.19 | 114.46 | 36.60% | |
| RGA | Reinsurance Group Of America | 275.15 | 93.35 | 51.35% | |
| RNR | Renaissancere | 353.62 | 92.30 | 35.32% | |
| SPNT | Siriuspoint Ltd | 26.57 | 6.84 | 34.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026